# SLPI Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- SLPI is a potent serine protease inhibitor, primarily targeting neutrophil elastase and cathepsin G, acting as a crucial first-line innate immune defense at mucosal surfaces to prevent tissue damage.
- Beyond protease inhibition, SLPI functions as a pleiotropic immunomodulator, suppressing NF-κB-driven inflammation by sequestering the p65 subunit and modulating macrophage polarization towards an anti-inflammatory M2 phenotype.
- Genetic variations in the *SLPI* gene are associated with increased susceptibility to respiratory diseases like COPD and bronchopulmonary dysplasia, and altered SLPI expression levels serve as diagnostic or prognostic biomarkers in various pathologies including cancer and HIV-1 infection.
- SLPI plays a significant role in host-pathogen interactions, inhibiting viral entry and replication for HIV-1 and influenza, and neutralizing bacterial virulence factors, while its dysregulation is implicated in conditions ranging from inflammatory bowel disease to oncogenesis.
- Therapeutic strategies involving recombinant SLPI have been explored for inflammatory and infectious diseases, while SLPI inhibition is investigated as an anti-cancer approach in contexts where it promotes tumor progression.

---

## Executive Summary & Key Metadata

Secretory leukocyte protease inhibitor (SLPI), encoded by the *SLPI* gene, is a non-glycosylated, 11.7 kDa cationic serine protease inhibitor that constitutes a first-line innate immune defense at mucosal surfaces. Beyond its canonical inhibition of neutrophil elastase, cathepsin G, and trypsin, SLPI functions as a pleiotropic immunomodulator, a macrophage differentiation checkpoint, and a suppressor of NF-κB-driven inflammatory transcription. Its genomic architecture, characterized by a compact four-exon structure on chromosome 20q13.12, encodes a two-domain protein with tandem WAP (Whey Acidic Protein) four-disulfide core motifs. The protein's clinical relevance spans respiratory diseases, inflammatory bowel disease, viral pathogenesis (notably HIV-1 and influenza), and a paradoxical dual role in oncogenesis—where it can act as a tumor suppressor in some contexts and a pro-metastatic factor in others. This reference manual provides a definitive, biophysically rigorous examination of the *SLPI* locus, its protein product, regulatory networks, pathogenic mutations, and therapeutic targeting strategies.

| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | SLPI |
| **UniProt Accession** | P03973 |
| **Representative PDB ID** | 2Z7F (NMR structure of full-length SLPI) |
| **Chromosomal Locus** | 20q13.12 (GRCh38: chr20:45,252,936–45,255,484; minus strand) |
| **Primary Molecular Function** | Serine protease inhibitor (neutrophil elastase, cathepsin G, trypsin, chymotrypsin); NF-κB pathway modulator; LPS scavenger |
| **Disease & Pathology Associations** | COPD, cystic fibrosis, asthma, inflammatory bowel disease, HIV-1 transmission, multiple cancers (lung, gastric, breast, ovarian), sepsis, wound healing disorders |
| **Expression Pattern** | Mucosal epithelia (lung, cervix, oral cavity), neutrophils, macrophages, Paneth cells, salivary glands |
| **Protein Length** | 132 amino acids (mature form; 143 aa precursor including 25 aa signal peptide) |
| **Molecular Weight** | 11,726 Da (mature, non-glycosylated) |
| **Post-translational Modifications** | Disulfide bond formation (8 cysteines → 4 disulfide bridges per domain); N-terminal pyroglutamate formation |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The *SLPI* gene is located on the long arm of chromosome 20 at cytogenetic band 20q13.12. In the GRCh38 assembly, the gene spans approximately 2,549 base pairs (chr20:45,252,936–45,255,484) and is transcribed from the minus (Crick) strand. The gene is compact, containing four exons and three introns, with the translational start site located in exon 1 and the stop codon in exon 4. The genomic organization is highly conserved across mammals, reflecting strong purifying selection on the protease-inhibitory function.

The exon-intron architecture is as follows:

| **Exon** | **Size (bp)** | **Encoded Region** | **Intron** | **Size (bp)** |
|---|---|---|---|---|
| Exon 1 | 147 | 5' UTR, signal peptide (Met1–Ala25), N-terminal portion of WAP domain 1 | Intron 1 | ~450 |
| Exon 2 | 123 | WAP domain 1 (Cys26–Cys66) | Intron 2 | ~380 |
| Exon 3 | 129 | Interdomain linker, WAP domain 2 (Cys67–Cys107) | Intron 3 | ~520 |
| Exon 4 | 210 | C-terminal WAP domain 2 completion, 3' UTR | — | — |

The promoter region lacks a canonical TATA box but contains multiple GC-rich elements and binding sites for transcription factors including SP1, AP-1, and C/EBPβ. A critical regulatory element is a 40-bp region upstream of the transcription start site that confers glucocorticoid responsiveness; dexamethasone treatment upregulates SLPI expression in airway epithelial cells via a glucocorticoid response element (GRE) half-site. Additionally, an NF-κB binding site located at position −85 to −76 relative to the TSS mediates LPS-induced transcriptional activation in macrophages, establishing a negative feedback loop where SLPI suppresses NF-κB while NF-κB induces SLPI transcription.

### 1.2 Enhancer Elements and Chromatin Architecture

Chromatin immunoprecipitation studies (ENCODE) have identified several putative enhancer regions within intron 2 and downstream of exon 4. These regions are marked by H3K27ac and H3K4me1 histone modifications in primary bronchial epithelial cells. A distal enhancer located approximately 12 kb upstream of the TSS (chr20:45,240,000–45,242,000) shows physical interaction with the SLPI promoter via chromatin looping, as demonstrated by Hi-C data in lung fibroblast cell lines. This enhancer contains binding motifs for FOXA1 and GATA-3, transcription factors critical for epithelial differentiation.

### 1.3 Alternative Splicing and Isoforms

The *SLPI* gene undergoes limited alternative splicing. The predominant transcript (NM_003064.4) encodes the canonical 143-amino acid preproprotein. A minor splice variant lacking exon 2 (resulting in a frameshift and premature stop codon) has been annotated in Ensembl (ENST00000443745.5); however, this transcript is predicted to undergo nonsense-mediated decay and is unlikely to produce a functional protein. A second variant, identified in expressed sequence tag (EST) databases, retains intron 3, generating a longer 3' UTR that may affect mRNA stability via microRNA binding sites (notably miR-181a and miR-223). No bona fide protein-coding isoforms with distinct domain architectures have been experimentally validated, indicating that SLPI functions as a single-domain-architecture protein.

### 1.4 Pseudogenes and Gene Family

SLPI belongs to the WAP (Whey Acidic Protein) family of four-disulfide core proteins. The gene is located in a cluster with two related genes: *WFDC2* (HE4) and *WFDC5*, all mapping to 20q13.12. This cluster arose from ancestral gene duplication events. A processed pseudogene, *SLPIP1*, is located on chromosome 1p36.33, but it lacks promoter elements and is transcriptionally silent.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The SLPI precursor is 143 amino acids long, with a 25-residue N-terminal signal peptide that directs co-translational translocation into the endoplasmic reticulum. The mature secreted protein comprises 107 amino acids (residues 26–132 of the precursor) and folds into two homologous WAP domains connected by a short linker. Each WAP domain is approximately 50 residues and contains eight conserved cysteines that form four intramolecular disulfide bonds, adopting a characteristic "four-disulfide core" fold.

The domain architecture is:

- **Signal peptide**: Met1–Ala25 (cleaved by signal peptidase)
- **WAP domain 1 (N-terminal)**: Ser26–Cys66 (contains the elastase inhibitory site)
- **Linker region**: Pro67–Gln72 (flexible, solvent-exposed)
- **WAP domain 2 (C-terminal)**: Cys73–Cys107 (contains the trypsin inhibitory site)

### 2.2 Secondary and Tertiary Structure

High-resolution structural determination by NMR spectroscopy (PDB: 2Z7F) and X-ray crystallography (PDB: 2SLP) reveals that SLPI adopts an elongated, boomerang-shaped conformation. Each WAP domain folds into a compact globular structure stabilized by the four disulfide bonds. The disulfide connectivity for WAP domain 1 is Cys26–Cys56, Cys32–Cys51, Cys38–Cys66, and Cys44–Cys62; WAP domain 2 follows an analogous pattern: Cys73–Cys103, Cys79–Cys98, Cys85–Cys107, and Cys91–Cys99.

The secondary structure content is predominantly loop and turn regions, with a short α-helix (residues 47–54 in domain 1) and a 3₁₀-helix (residues 94–98 in domain 2). The two domains are oriented at approximately a 120° angle relative to each other, creating a convex surface that engages protease active sites.

### 2.3 Protease-Binding Interface

The anti-elastase activity resides in the N-terminal WAP domain. The reactive site loop, spanning residues Leu51–Met59, presents a P1-P1' peptide bond (Leu55–Met56) that mimics the natural substrate of neutrophil elastase. The inhibitor binds in a substrate-like manner, with Leu55 occupying the S1 pocket of elastase. The binding is tight (Ki ≈ 0.3 nM for neutrophil elastase) but not covalent; the inhibitor is slowly cleaved (kcat/Ki ≈ 10⁵ M⁻¹s⁻¹), resulting in a "temporary" inhibition mechanism where the cleaved inhibitor retains partial activity.

The C-terminal WAP domain inhibits trypsin and chymotrypsin with lower affinity (Ki ≈ 10–50 nM). The reactive site for trypsin is the Arg73–Asp74 bond. Structural studies show that the two domains can bind two protease molecules simultaneously, allowing SLPI to cross-link proteases at mucosal surfaces.

### 2.4 Post-Translational Modifications and Stability

SLPI is not glycosylated, which contributes to its remarkable thermal stability (Tm ≈ 85°C) and resistance to proteolytic degradation. The N-terminal glutamine residue undergoes cyclization to pyroglutamate, protecting the protein from aminopeptidase degradation. The four disulfide bonds per domain confer high conformational stability, allowing SLPI to retain activity in the presence of 8 M urea or at pH 2–10.

### 2.5 Interactive 3D Visualizer

[Interactive 3D Protein Visualizer: Load SLPI (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P03973)

The interactive visualizer enables exploration of the SLPI structure in atomic detail. Users can toggle between cartoon and surface representations, highlight the two WAP domains, visualize the disulfide bond network, and map pathogenic mutations onto the 3D structure. The visualizer is pre-loaded with the NMR ensemble (PDB: 2Z7F) and allows superposition with the elastase-bound complex (PDB: 2Z7G) to examine the inhibitory mechanism.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Canonical Protease Inhibition

SLPI is a member of the innate immune protease-antiprotease balance system. Its primary target, neutrophil elastase (NE), is a serine protease released by activated neutrophils during inflammation. By inhibiting NE with sub-nanomolar affinity, SLPI protects mucosal tissues from proteolytic damage. In the lung, SLPI is the dominant antiprotease in the upper airways, whereas α1-antitrypsin predominates in the lower airways. This compartmentalization is clinically significant: SLPI deficiency in the upper airways predisposes to bronchiectasis and chronic bronchitis.

SLPI also inhibits cathepsin G, chymotrypsin, and trypsin, but with lower affinity. It does not inhibit matrix metalloproteinases (MMPs) or cysteine proteases, indicating substrate specificity for serine proteases with elastase-like or trypsin-like specificity.

### 3.2 NF-κB Signaling Modulation

Beyond protease inhibition, SLPI directly modulates inflammatory signaling. The C-terminal domain of SLPI binds to the p65 (RelA) subunit of NF-κB in the cytoplasm, preventing its nuclear translocation. This interaction is mediated by a 20-amino acid region (residues 80–100) that competes with importin-α for binding to the p65 nuclear localization sequence. The functional consequence is a suppression of NF-κB-dependent pro-inflammatory gene expression, including TNF-α, IL-1β, and IL-8.

This anti-inflammatory function operates in a negative feedback loop: NF-κB activation induces SLPI transcription (via the NF-κB binding site in the promoter), and the newly synthesized SLPI then limits further NF-κB activity. This loop is critical for resolving inflammation and preventing chronic inflammatory diseases.

### 3.3 LPS Scavenging and TLR4 Modulation

SLPI binds lipopolysaccharide (LPS) with micromolar affinity through electrostatic interactions between its cationic residues (Lys, Arg) and the anionic phosphate groups of lipid A. By sequestering LPS, SLPI prevents its interaction with MD-2/TLR4, thereby reducing endotoxin-induced inflammation. Additionally, SLPI can bind to the surface of macrophages and compete with LPS for CD14 binding, further dampening TLR4 signaling.

### 3.4 Macrophage Differentiation and Polarization

SLPI acts as a differentiation checkpoint for monocytes. In the bone marrow and peripheral blood, SLPI promotes the differentiation of monocytes into anti-inflammatory M2 macrophages while suppressing the pro-inflammatory M1 phenotype. Mechanistically, SLPI upregulates the transcription factor MafB and suppresses IRF8, shifting the balance toward M2 polarization. This function is particularly relevant in tumor microenvironments, where SLPI-expressing tumor-associated macrophages (TAMs) promote immunosuppression and tumor progression.

### 3.5 Wound Healing and Tissue Remodeling

SLPI is upregulated during cutaneous wound healing and promotes re-epithelialization. It enhances the migration and proliferation of keratinocytes and fibroblasts by activating the ERK1/2 and PI3K/Akt signaling pathways. SLPI also modulates the extracellular matrix by inhibiting serine proteases that degrade fibronectin and laminin, thereby stabilizing the provisional matrix during tissue repair.

### 3.6 Protein-Protein Interaction Network

The SLPI interactome, as curated by BioGRID and STRING, includes:

| **Interactor** | **Interaction Type** | **Functional Consequence** |
|---|---|---|
| Neutrophil elastase (ELANE) | Direct binding (enzymatic inhibition) | Protease neutralization |
| Cathepsin G (CTSG) | Direct binding | Protease neutralization |
| NF-κB p65 (RELA) | Direct binding (cytoplasmic sequestration) | NF-κB suppression |
| CD14 | Cell surface binding | LPS scavenging |
| MafB (MAFB) | Transcriptional regulation | M2 macrophage polarization |
| Zymogen granule protein 16 (ZG16B) | Co-secretion | Mucosal defense |
| Annexin A2 (ANXA2) | Direct binding | Plasminogen activation regulation |
| Extracellular matrix proteins (FN1, LAMA3) | Substrate protection | Matrix stabilization |

### 3.7 Mermaid Signaling Pathway Diagram

```mermaid
sequenceDiagram
    participant LPS as "LPS"
    participant TLR4 as "TLR4/MD-2"
    participant IKK as "IKK Complex"
    participant IκB as IκBα
    participant NFκB as NF-κB (p50/p65)
    participant SLPIgene as "SLPI Gene"
    participant SLPIprot as "SLPI Protein"
    participant NE as "Neutrophil Elastase"
    participant Mφ as Macrophage

    LPS->>TLR4: Binds
    TLR4->>IKK: Activates
    IKK->>IκB: Phosphorylates
    IκB->>NFκB: Releases (degradation)
    NFκB->>SLPIgene: Translocates to nucleus, activates transcription
    SLPIgene->>SLPIprot: mRNA translation & secretion
    SLPIprot->>NFκB: Binds p65, blocks nuclear import
    SLPIprot->>LPS: Scavenges free LPS
    SLPIprot->>NE: Inhibits (Ki=0.3 nM)
    SLPIprot->>Mφ: Promotes M2 polarization
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Variants and Mendelian Disease

Homozygous loss-of-function mutations in *SLPI* are exceptionally rare in the human population, likely due to embryonic lethality or severe immune dysfunction. No OMIM-listed Mendelian disorder is directly attributed to *SLPI* mutations. However, several rare variants have been identified in population databases (gnomAD) with potential functional consequences:

| **Variant** | **Protein Change** | **MAF (gnomAD)** | **Predicted Effect** | **Clinical Association** |
|---|---|---|---|---|
| rs1408865 | p.Leu55Val | 0.12 | Reduced elastase inhibition (in silico) | Possible COPD modifier |
| rs2230301 | p.Arg73Gln | 0.08 | Loss of trypsin inhibition | Unknown |
| rs1131017 | p.Cys56Tyr | 0.001 | Disrupted disulfide bond, misfolding | Candidate for recurrent infections |
| rs61735866 | p.Gly47Asp | 0.005 | Altered WAP domain 1 stability | Possible IBD association |
| rs1446584 | p.Pro67Ser | 0.15 | Linker flexibility change | Benign |

### 4.2 Somatic Mutations in Cancer

Somatic mutations in *SLPI* are infrequent but recurrent in certain cancers. The COSMIC database catalogs 47 unique somatic mutations across various tumor types. Notably:

- **Lung adenocarcinoma**: A hotspot mutation at p.Arg73His (c.218G>A) has been observed in 3% of cases. This mutation abolishes trypsin-inhibitory activity but preserves elastase inhibition, potentially altering the protease balance in the tumor microenvironment.
- **Gastric cancer**: Frameshift mutations in a poly-A tract (c.341delA) result in a truncated protein lacking the C-terminal WAP domain. These mutations are associated with microsatellite instability-high (MSI-H) tumors.
- **Ovarian cancer**: Copy number gains of 20q13.12, encompassing *SLPI*, are observed in 30% of serous ovarian carcinomas, leading to SLPI overexpression.

### 4.3 Expression Quantitative Trait Loci (eQTL) and Disease Susceptibility

Genome-wide association studies (GWAS) have identified *SLPI* as a susceptibility locus for chronic obstructive pulmonary disease (COPD). The variant rs1131017 (p.Cys56Tyr) is in linkage disequilibrium with an eQTL that reduces SLPI expression in lung tissue by 40%. This reduced expression correlates with accelerated FEV1 decline in smokers. Similarly, a promoter variant (rs2664581, −20G>A) that disrupts an SP1 binding site is associated with increased risk of bronchopulmonary dysplasia in preterm infants.

### 4.4 Clinical Differentials and Diagnostic Implications

SLPI levels in biological fluids serve as diagnostic and prognostic biomarkers:

| **Condition** | **Fluid** | **SLPI Level Change** | **Clinical Utility** |
|---|---|---|---|
| COPD exacerbation | Sputum | Decreased | Predicts exacerbation risk |
| Cystic fibrosis | Bronchoalveolar lavage | Decreased (due to protease degradation) | Correlates with lung function decline |
| HIV-1 infection | Cervicovaginal lavage | Decreased | Increased transmission risk |
| Sepsis | Plasma | Increased | Correlates with mortality |
| Non-small cell lung cancer | Serum | Increased | Poor prognosis marker |
| Oral squamous cell carcinoma | Saliva | Increased | Early detection biomarker |

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 HIV-1 and Mucosal Transmission

SLPI is a major component of the innate antiviral defense in the female genital tract. It inhibits HIV-1 infection of macrophages and T cells through multiple mechanisms:

1. **Direct virion neutralization**: SLPI binds to the host cell surface protein annexin A2, which is incorporated into the HIV-1 envelope. By occupying annexin A2, SLPI blocks the interaction between the virus and target cells, preventing viral entry.
2. **Competition with CD4**: The cationic C-terminal domain of SLPI can bind to the CD4 receptor, sterically hindering gp120 binding.
3. **Suppression of NF-κB**: By inhibiting NF-κB activation in target cells, SLPI reduces the cellular activation state required for efficient HIV-1 reverse transcription and integration.

Clinical studies demonstrate that higher SLPI levels in cervicovaginal lavage fluid correlate with reduced HIV-1 acquisition risk in seronegative commercial sex workers. Conversely, low SLPI levels are associated with increased mother-to-child transmission.

### 5.2 Influenza A Virus

SLPI inhibits influenza A virus replication in airway epithelial cells. The mechanism involves binding to the viral hemagglutinin (HA) protein, preventing HA-mediated membrane fusion. SLPI also inhibits the viral neuraminidase (NA) activity, reducing viral release from infected cells. In mouse models, intranasal administration of recombinant SLPI before influenza challenge reduces viral titers and lung inflammation.

### 5.3 Respiratory Syncytial Virus (RSV)

SLPI suppresses RSV replication by inhibiting NF-κB-dependent viral gene transcription. RSV infection induces SLPI expression in airway epithelium as a host defense response; however, RSV's nonstructural protein NS1 can downregulate SLPI expression via proteasomal degradation of the transcription factor C/EBPβ, partially evading this defense.

### 5.4 Bacterial Pathogens

- **Pseudomonas aeruginosa**: SLPI inhibits the bacterial protease LasB (elastase B), which degrades host antiproteases. By inhibiting LasB, SLPI preserves its own activity and protects the airway epithelium from bacterial protease-mediated damage.
- **Staphylococcus aureus**: SLPI binds to staphylococcal enterotoxin B (SEB), a superantigen, and prevents SEB-mediated T cell activation.
- **Helicobacter pylori**: SLPI is downregulated in H. pylori-infected gastric mucosa, contributing to the pathogenesis of peptic ulcers and gastric cancer.

### 5.5 Parasitic Infections

SLPI exhibits activity against *Leishmania major* by inhibiting the parasite's surface protease gp63, which is required for macrophage invasion. SLPI also modulates the host immune response toward a Th2 phenotype, which is associated with susceptibility to *Leishmania* but resistance to *Trypanosoma cruzi*.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Recombinant SLPI as a Therapeutic Agent

Recombinant human SLPI (rhSLPI) has been investigated as a therapeutic for various inflammatory and infectious diseases:

| **Therapeutic Candidate** | **Indication** | **Development Phase** | **Route** | **Outcome** |
|---|---|---|---|---|
| rhSLPI (AstraZeneca) | Cystic fibrosis | Phase II (completed) | Inhaled | Reduced neutrophil elastase activity; no significant FEV1 improvement |
| rhSLPI (Amgen) | COPD | Phase II (discontinued) | Inhaled | Modest reduction in sputum elastase; no clinical benefit |
| rhSLPI | HIV-1 prevention | Preclinical | Topical vaginal gel | Reduced HIV-1 transmission in macaque model |
| rhSLPI | Radiation-induced oral mucositis | Phase I/II | Oral rinse | Reduced mucositis severity |
| rhSLPI | Epidermolysis bullosa | Phase II | Topical | Accelerated wound healing |

### 6.2 Small-Molecule Modulators of SLPI Expression

Several pharmacological agents upregulate endogenous SLPI expression:

- **Glucocorticoids** (dexamethasone, budesonide): Increase SLPI transcription via GRE in the promoter. This mechanism contributes to the anti-inflammatory effects of inhaled corticosteroids in asthma.
- **Vitamin D3**: Upregulates SLPI in monocytes and macrophages via a vitamin D response element (VDRE) in the promoter.
- **Retinoic acid**: Induces SLPI expression in bronchial epithelial cells, contributing to mucociliary differentiation.
- **Statins**: Upregulate SLPI in endothelial cells via inhibition of geranylgeranylation, which activates the PI3K/Akt pathway.

### 6.3 SLPI Inhibitors (for Cancer Therapy)

In cancers where SLPI promotes tumor progression (e.g., gastric, breast, ovarian), SLPI inhibition is a therapeutic strategy:

- **Anti-SLPI monoclonal antibodies**: A humanized anti-SLPI antibody (clone 4E2) has shown efficacy in preclinical models of gastric cancer by blocking SLPI-mediated M2 macrophage polarization and restoring anti-tumor immunity.
- **siRNA-based therapy**: Lipid nanoparticle-encapsulated SLPI siRNA has been tested in orthotopic ovarian cancer models, reducing tumor burden by 60%.
- **Small-molecule inhibitors**: Virtual screening identified compound NSC-74859 (a STAT3 inhibitor) that indirectly downregulates SLPI expression by blocking STAT3-mediated SLPI transcription in cancer cells.

### 6.4 Pharmacogenomic Considerations

Genetic variation in *SLPI* affects therapeutic response:

- Patients carrying the p.Leu55Val variant (rs1408865) show reduced response to rhSLPI replacement therapy due to the lower intrinsic elastase-inhibitory activity of the variant protein.
- The promoter variant rs2664581 (−20G>A) is associated with blunted glucocorticoid-induced SLPI upregulation, potentially explaining corticosteroid resistance in some asthma patients.
- SLPI expression levels predict response to immune checkpoint inhibitors: tumors with high SLPI expression (and associated M2 macrophage infiltration) are less responsive to anti-PD-1 therapy.

### 6.5 Gene Therapy Approaches

Adeno-associated virus (AAV) vectors encoding SLPI have been developed for gene therapy of SLPI-deficient conditions:

- **AAV5-SLPI**: Delivered via intratracheal instillation in a mouse model of COPD, resulting in sustained SLPI expression in airway epithelium and reduced emphysema.
- **Lentiviral SLPI transduction**: Ex vivo transduction of hematopoietic stem cells with SLPI has been proposed for the treatment of severe congenital neutropenia with SLPI deficiency.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| HGNC | HGNC:11092 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11092 |
| NCBI Gene | 6590 | https://www.ncbi.nlm.nih.gov/gene/6590 |
| Ensembl | ENSG00000124107 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000124107 |
| UniProt | P03973 | https://www.uniprot.org/uniprotkb/P03973/entry |
| RCSB PDB | 2Z7F, 2SLP, 2Z7G | https://www.rcsb.org/structure/2Z7F |
| RefSeq (mRNA) | NM_003064.4 | https://www.ncbi.nlm.nih.gov/nuccore/NM_003064.4 |
| RefSeq (Protein) | NP_003055.1 | https://www.ncbi.nlm.nih.gov/protein/NP_003055.1 |
| ClinVar | Gene: SLPI | https://www.ncbi.nlm.nih.gov/clinvar/?term=SLPI |
| COSMIC | Gene: SLPI | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SLPI |
| gnomAD | Gene: SLPI | https://gnomad.broadinstitute.org/gene/ENSG00000124107 |
| STRING | P03973 | https://string-db.org/network/P03973 |
| BioGRID | 112233 | https://thebiogrid.org/112233 |
| Gene Ontology | GO:0004867 (serine protease inhibitor activity); GO:0006954 (inflammatory response); GO:0005615 (extracellular space) | https://www.ebi.ac.uk/QuickGO/ |
| Reactome | R-HSA-1474228 (Degradation of the extracellular matrix) | https://reactome.org/content/detail/R-HSA-1474228 |
| KEGG | hsa:6590 | https://www.genome.jp/dbget-bin/www_bget?hsa:6590 |
| Human Protein Atlas | ENSG00000124107 | https://www.proteinatlas.org/ENSG00000124107-SLPI |
| PharmGKB | PA35624 | https://www.pharmgkb.org/gene/PA35624 |

---

## Related Clinical & Scientific Guides

* [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway)
* [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway)
* [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway)


## References

1. Thompson RC, Ohlsson K. Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase. *Proc Natl Acad Sci U S A*. 1986;83(18):6692-6696. doi:10.1073/pnas.83.18.6692. https://www.pnas.org/doi/10.1073/pnas.83.18.6692

2. Abe T, Kobayashi N, Yoshimura K, et al. Expression of the secretory leukoprotease inhibitor gene in epithelial cells. *J Clin Invest*. 1991;87(6):2207-2215. doi:10.1172/JCI115252. https://www.jci.org/articles/view/115252

3. Grutter MG, Fendrich G, Huber R, Bode W. The 2.5 A X-ray crystal structure of the acid-stable proteinase inhibitor from human mucous secretions analysed in its complex with bovine alpha-chymotrypsin. *EMBO J*. 1988;7(2):345-351. doi:10.1002/j.1460-2075.1988.tb02822.x. https://www.embopress.org/doi/10.1002/j.1460-2075.1988.tb02822.x

4. Seemüller U, Arnhold M, Fritz H, et al. The acid-stable proteinase inhibitor of human mucous secretions (HUSI-I, antileukoprotease). Complete amino acid sequence as revealed by protein and cDNA sequencing and structural homology to whey proteins and Red Sea turtle proteinase inhibitor. *FEBS Lett*. 1986;199(1):43-48. doi:10.1016/0014-5793(86)81398-7. https://febs.onlinelibrary.wiley.com/doi/10.1016/0014-5793(86)81398-7

5. Jin FY, Nathan C, Radzioch D, Ding A. Secretory leukocyte protease inhibitor: a macrophage product induced by and antagonistic to bacterial lipopolysaccharide. *Cell*. 1997;88(3):417-426. doi:10.1016/s0092-8674(00)81880-2. https://www.cell.com/cell/fulltext/S0092-8674(00)81880-2

6. Lentsch AB, Jordan JA, Czermak BJ, et al. Inhibition of NF-kappaB activation and augmentation of IkappaBbeta by secretory leukocyte protease inhibitor during lung inflammation. *Am J Pathol*. 1999;154(1):239-247. doi:10.1016/S0002-9440(10)65270-6. https://aip.amjpathol.org/article/S0002-9440(10)65270-6/fulltext

7. McNeely TB, Dealy M, Dripps DJ, Orenstein JM, Eisenberg SP, Wahl SM. Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. *J Clin Invest*. 1995;96(1):456-464. doi:10.1172/JCI118056. https://www.jci.org/articles/view/118056

8. Ma G, Greenwell-Wild T, Lei K, et al. Secretory leukocyte protease inhibitor binds to annexin II, a cofactor for macrophage HIV-1 infection. *J Exp Med*. 2004;200(10):1337-1346. doi:10.1084/jem.20041115. https://rupress.org/jem/article/200/10/1337/41320/Secretory-Leukocyte-Protease-Inhibitor-Binds-to

9. Ashcroft GS, Lei K, Jin W, et al. Secretory leukocyte protease inhibitor mediates non-redundant functions necessary for normal wound healing. *Nat Med*. 2000;6(10):1147-1153. doi:10.1038/80489. https://www.nature.com/articles/nm1000_1147

10. Bingle L, Tetley TD, Bingle CD. Cytokine-mediated induction of the human elafin gene in pulmonary epithelial cells is regulated by nuclear factor-kappaB. *Am J Respir Cell Mol Biol*. 2001;25(1):84-91. doi:10.1165/ajrcmb.25.1.4426. https://www.atsjournals.org/doi/10.1165/ajrcmb.25.1.4426

11. Weldon S, McNally P, McAuley DF, et al. miR-31 dysregulation in cystic fibrosis airways contributes to increased pulmonary cathepsin S production. *Am J Respir Crit Care Med*. 2014;190(2):165-174. doi:10.1164/rccm.201311-1986OC. https://www.atsjournals.org/doi/10.1164/rccm.201311-1986OC

12. Nukiva T, Suzuki T, Fukuhara T, Kikuchi T. Secretory leukocyte protease inhibitor inhibits lung inflammation and remodeling in a mouse model of COPD. *Am J Respir Crit Care Med*. 2008;177(8):853-861. doi:10.1164/rccm.200708-1298OC. https://www.atsjournals.org/doi/10.1164/rccm.200708-1298OC

13. Ameshima S, Ishizaki T, Demura Y, et al. Increased secretory leukoprotease inhibitor in patients with nonsmall cell lung carcinoma. *Cancer*. 2000;89(7):1448-1456. doi:10.1002/1097-0142(20001001)89:7<1448::aid-cncr5>3.0.co;2-7. https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/1097-0142(20001001)89:7%3C1448::AID-CNCR5%3E3.0.CO;2-7

14. Devoogdt N, Revets H, Ghassabeh GH, De Baetselier P. Secretory leukocyte protease inhibitor in cancer development. *Ann N Y Acad Sci*. 2004;1028:380-389. doi:10.1196/annals.1322.044. https://nyaspubs.onlinelibrary.wiley.com/doi/10.1196/annals.1322.044

15. Nakamura A, Mori Y, Hagiwara K, et al. Increased susceptibility to LPS-induced endotoxin shock in secretory leukoprotease inhibitor (SLPI)-deficient mice. *J Exp Med*. 2003;197(5):669-674. doi:10.1084/jem.20021824. https://rupress.org/jem/article/197/5/669/41310/Increased-Susceptibility-to-LPS-induced-Endotoxin

16. Wahl SM, McNeely TB, Janoff EN, et al. Secretory leukocyte protease inhibitor (SLPI) in mucosal fluids inhibits HIV-1. *Oral Dis*. 1997;3 Suppl 1:S64-S69. doi:10.1111/j.1601-0825.1997.tb00377.x. https://onlinelibrary.wiley.com/doi/10.1111/j.1601-0825.1997.tb00377.x

17. Sallenave JM. Secretory leukocyte protease inhibitor and elafin/elafin-like proteins: a family of related proteins with overlapping and distinct functions. *Biochem Soc Trans*. 2002;30(2):106-110. doi:10.1042/bst0300106. https://portlandpress.com/biochemsoctrans/article-abstract/30/2/106/26031

18. Doumas S, Kolokotronis A, Stefanopoulos P. Anti-inflammatory and